Melissa A Tapia1, John R Lever2, Susan Z Lever3, Matthew J Will4, Eric S Park4, Dennis K Miller4. 1. Department of Psychological Sciences, University of Missouri, 210 McAlester Hall, Columbia, MO, 65211, USA. matb6b@mail.missouri.edu. 2. Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, and Department of Radiology and Radiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO, 65211, USA. 3. Department of Chemistry and MU Research Reactor Center, University of Missouri, Columbia, MO, 65211, USA. 4. Department of Psychological Sciences, University of Missouri, 210 McAlester Hall, Columbia, MO, 65211, USA.
Abstract
RATIONALE: Previous research indicates that the selective sigma-1 receptor ligand PD144418 and the selective sigma-2 ligands YUN-252 can inhibit cocaine-induced hyperactivity. The effects of these ligands on other stimulants, such as methamphetamine, have not been reported. OBJECTIVES: The present study examined the effects of PD144418 and YUN-252 pretreatment on methamphetamine-induced hyperactivity after acute treatment. METHODS: Mice (n = 8-14/group) were injected with PD144418 (3.16, 10, or 31.6 μmol/kg), YUN-252 (0.316, 3.16, 31.6 μmol/kg), or saline. After 15 min, mice injected with 2.69 μmol/kg methamphetamine or saline vehicle, where distance traveled during a 60-min period was recorded. Additionally, the effect of PD144418 on the initiation and expression of methamphetamine sensitization was determined by treating mice (n = 8-14/group) with PD144418, methamphetamine or saline repeatedly over a 5-day period, and testing said mice with a challenge dose after a 7-day withdrawal period. RESULTS: Results indicate that both PD144418 and YUN-252, in a dose-dependent manner, attenuated hyperactivity induced by an acute methamphetamine injection. Specifically, 10 μmol/kg or 31.6 μmol/kg of PD144418 and 31 μmol/kg of YUN-252 suppressed methamphetamine-induced hyperactivity. In regard to methamphetamine sensitization, while 10 μmol/kg PD144418 prevented the initiation of methamphetamine sensitization, it did not have an effect on the expression. CONCLUSIONS: Overall, the current results suggest an intriguing potential for this novel sigma receptor ligand as a treatment for the addictive properties of methamphetamine. Future analysis of this novel sigma receptor ligand in assays directly measuring reinforcement properties will be critical.
RATIONALE: Previous research indicates that the selective sigma-1 receptor ligand PD144418 and the selective sigma-2 ligands YUN-252 can inhibit cocaine-induced hyperactivity. The effects of these ligands on other stimulants, such as methamphetamine, have not been reported. OBJECTIVES: The present study examined the effects of PD144418 and YUN-252 pretreatment on methamphetamine-induced hyperactivity after acute treatment. METHODS: Mice (n = 8-14/group) were injected with PD144418 (3.16, 10, or 31.6 μmol/kg), YUN-252 (0.316, 3.16, 31.6 μmol/kg), or saline. After 15 min, mice injected with 2.69 μmol/kg methamphetamine or saline vehicle, where distance traveled during a 60-min period was recorded. Additionally, the effect of PD144418 on the initiation and expression of methamphetamine sensitization was determined by treating mice (n = 8-14/group) with PD144418, methamphetamine or saline repeatedly over a 5-day period, and testing said mice with a challenge dose after a 7-day withdrawal period. RESULTS: Results indicate that both PD144418 and YUN-252, in a dose-dependent manner, attenuated hyperactivity induced by an acute methamphetamine injection. Specifically, 10 μmol/kg or 31.6 μmol/kg of PD144418 and 31 μmol/kg of YUN-252 suppressed methamphetamine-induced hyperactivity. In regard to methamphetamine sensitization, while 10 μmol/kg PD144418 prevented the initiation of methamphetamine sensitization, it did not have an effect on the expression. CONCLUSIONS: Overall, the current results suggest an intriguing potential for this novel sigma receptor ligand as a treatment for the addictive properties of methamphetamine. Future analysis of this novel sigma receptor ligand in assays directly measuring reinforcement properties will be critical.
Authors: Nidhi Kaushal; Matthew J Robson; Harsha Vinnakota; Sanju Narayanan; Bonnie A Avery; Christopher R McCurdy; Rae R Matsumoto Journal: AAPS J Date: 2011-04-15 Impact factor: 4.009
Authors: Angelo Blasio; Marta Valenza; Malliga R Iyer; Kenner C Rice; Luca Steardo; T Hayashi; Pietro Cottone; Valentina Sabino Journal: Behav Brain Res Date: 2015-04-04 Impact factor: 3.332
Authors: Jonathan L Katz; Takato Hiranita; Theresa A Kopajtic; Kenner C Rice; Christophe Mesangeau; Sanju Narayanan; Ahmed H Abdelazeem; Christopher R McCurdy Journal: J Pharmacol Exp Ther Date: 2016-04-21 Impact factor: 4.030
Authors: John R Lever; Dennis K Miller; Emily A Fergason-Cantrell; Caroline L Green; Lisa D Watkinson; Terry L Carmack; Susan Z Lever Journal: J Pharmacol Exp Ther Date: 2014-08-06 Impact factor: 4.030
Authors: Xinying Liu; Yingmei Fu; Huan Yang; Timur Mavlyutov; Jun Li; Christopher R McCurdy; Lian-Wang Guo; Bikash R Pattnaik Journal: Oncotarget Date: 2017-07-26
Authors: Anna M Klawonn; Anna Nilsson; Carl F Rådberg; Sarah H Lindström; Mia Ericson; Björn Granseth; David Engblom; Michael Fritz Journal: Front Pharmacol Date: 2017-10-10 Impact factor: 5.810
Authors: Lisa L Wilson; Shainnel O Eans; Insitar Ramadan-Siraj; Maria N Modica; Giuseppe Romeo; Sebastiano Intagliata; Jay P McLaughlin Journal: Int J Mol Sci Date: 2022-01-06 Impact factor: 5.923